Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 1 year ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
AHA 24: The LIBerate-HeFH_OLE Study
Author(s): Frederick Raal Added: 7 months ago
AHA Conference 2024 - Long-term safety and efficacy outcomes of lerodalcibep, a third generation PCSK9 inhibitor (LIB Therapeutics LLC), in heterozygous familial hypercholesterolemia (HoFH) subjects.Prof Frederick Raal (University of the Witwatersrand, ZA) joins us onsite at AHA Conference to discuss the findings from LIBerate-HeFH_OLE (NCT04798430; LIB Therapeutics).LIBerate-HeFH_OLE is an open… View more

Prevention & Chronic Conditions
Research Area(s) / Expertise: Job title: Founder of the Lipid Research Clinic
Research Area(s) / Expertise:
Frederick Raal
Research Area(s) / Expertise: Job title: Professor and Director of the Carbohydrate and Lipid Metabolism Research Unit
Professor Frederick Raal is a distinguished Professor and the Director of the Carbohydrate and Lipid Metabolism Research Unit at the University of the Witwatersrand in Johannesburg, South Africa. He also serves as the Head of the Division of Endocrinology and Metabolism at the same institution.He graduated with an MBBCh degree in 1981, followed by a Master of Medicine in 1991, a PhD in 2000, and… View more
AHA 24: The BROOKLYN Study
Author(s): Stephen Nicholls Added: 6 months ago
AHA Conference 2024 - BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).BROOKLYN is a phase 3,… View more

Prevention & Chronic Conditions
PCSK9 Inhibition: The Big Step Forward in Lipid Control
Author(s): Rishi Rikhi , Michael D Shapiro Added: 1 year ago

Vascular Disease and Surgery

Prevention & Chronic Conditions
Remnant Lipoproteins and ASCVD
Author(s): Mohanad Gabani , Michael D Shapiro , Peter P Toth Added: 1 year ago

Prevention & Chronic Conditions
AHA 2023 Late-Breaking Science Lineup Revealed
Added: 1 year ago Source:  AHA
AUTHOR: Jordan RanceThe American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals.Among the event’s highlights are eight late-breaking trial sessions, as listed below.Watch our… View more
Michael Koren is a practising cardiologist and Chief Executive Officer at Jacksonville Center for Clinical Research, overseeing clinical trials across eight sites in Florida. He earned his medical degree cum laude from Harvard Medical School and completed his residency in internal medicine and fellowship in cardiology at NewYork Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical… View more